foretinib   Click here for help

GtoPdb Ligand ID: 5679

Synonyms: EXEL-2880 | GSK 1363089G | GSK1363089 | XL 880
PDB Ligand
Compound class: Synthetic organic
Comment: Foretinib is a small molecule ATP-competitive inhibitor principally of the protein kinases c-Met (HGFR) and vascular endothelial growth factor receptor 2 (VEGFR2, aka KDR) [4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 14
Topological polar surface area 111.25
Molecular weight 632.24
XLogP 4.55
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES COc1cc2c(ccnc2cc1OCCCN1CCOCC1)Oc1ccc(cc1F)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F
Isomeric SMILES COc1cc2c(ccnc2cc1OCCCN1CCOCC1)Oc1ccc(cc1F)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F
InChI InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
No information available.
Summary of Clinical Use Click here for help
Foretinib was evaluated in several Phase 2 clinical trials as a treatment for many cancer types, including recurrent or metastatic squamous cell cancer of the head and neck, metastatic gastric cancer, renal cell carcinoma (RCC), metastatic breast cancer and advanced or metastatic non-small cell lung cancer (NSCLC). Development was terminated at Phase 2.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Foretinib acts to reduce tumour growth through inhibition of proliferation of tumour cells and inhibition of invasion and angiogenesis [4].